These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1888633)

  • 1. COMT inhibition with nitecapone does not affect the tyramine pressor response.
    Sundberg S; Gordin A
    Br J Clin Pharmacol; 1991 Jul; 32(1):130-2. PubMed ID: 1888633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
    Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
    Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.
    Schultz E; Tarpila S; Bäckström AC; Gordin A; Nissinen E; Pohto P
    Eur J Clin Pharmacol; 1991; 40(6):577-80. PubMed ID: 1884738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
    Cedarbaum JM; Léger G; Reches A; Guttman M
    Clin Neuropharmacol; 1990 Dec; 13(6):544-52. PubMed ID: 2276119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
    Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
    Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous tyramine pressor response in depression.
    Ghose K; Turner P
    Lancet; 1975 Jun; 1(7920):1317-8. PubMed ID: 49518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of catechol-O-methyltransferase sensitize mice to pain.
    Kambur O; Talka R; Ansah OB; Kontinen VK; Pertovaara A; Kalso E; Männistö PT
    Br J Pharmacol; 2010 Dec; 161(7):1553-65. PubMed ID: 20726980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.
    Sundberg S; Scheinin M; Illi A; Akkila J; Gordin A; Keränen T
    Br J Clin Pharmacol; 1993 Nov; 36(5):451-6. PubMed ID: 12959293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds.
    Flemström G; Säfsten B; Jedstedt G
    Gastroenterology; 1993 Mar; 104(3):825-33. PubMed ID: 8095035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
    Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
    Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
    Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury.
    Haramaki N; Stewart DB; Aggarwal S; Kawabata T; Packer L
    Biochem Pharmacol; 1995 Sep; 50(6):839-43. PubMed ID: 7575646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 17. Antioxidant properties of nitecapone (OR-462).
    Suzuki YJ; Tsuchiya M; Safadi A; Kagan VE; Packer L
    Free Radic Biol Med; 1992 Nov; 13(5):517-25. PubMed ID: 1334029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats.
    Kambur O; Männistö PT; Pusa AM; Käenmäki M; Kalso EA; Kontinen VK
    Eur J Pain; 2011 Aug; 15(7):732-40. PubMed ID: 21216640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.
    Nissinen E; Lindén IB; Schultz E; Kaakkola S; Männistö PT; Pohto P
    Eur J Pharmacol; 1988 Aug; 153(2-3):263-9. PubMed ID: 3181288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.
    Wikberg T; Taskinen J
    J Pharm Biomed Anal; 1991; 9(1):59-64. PubMed ID: 2043724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.